公开(公告)号：WO2004022054A1

公开(公告)日：2004-03-18

申请号：PCT/US2003/027722

申请日：2003-09-05

Applicant: BIOGEN, INC. ,  LEE, Wen-Cherng ,  CARTER, Mary, Beth ,  SUN, Lihong ,  LYNE, Paul ,  CHUAQUI, Claudio ,  ZHENG, Zhongli ,  SINGH, Juswinder ,  BORIACK-SJODIN, Paula

Inventor： LEE, Wen-Cherng ,  CARTER, Mary, Beth ,  SUN, Lihong ,  LYNE, Paul ,  CHUAQUI, Claudio ,  ZHENG, Zhongli ,  SINGH, Juswinder ,  BORIACK-SJODIN, Paula

IPC: A61K31/415

CPC classification number: C07D487/04 ,  C07D471/04

Abstract: Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I:

Abstract translation: 式I化合物对Alk 5和/或Alk 4具有出人意料的高亲和力，并且可用作其拮抗剂，用于预防和/或治疗包括纤维化疾病在内的许多疾病。 在一个实施方案中，本发明的特征在于式I的化合物：

公开(公告)号：WO2004021989A2

公开(公告)日：2004-03-18

申请号：PCT/US2003/027721

申请日：2003-09-05

Applicant: BIOGEN, INC. ,  LEE, Wen-Cherng ,  CARTER, Mary, Beth ,  SUN, Lihong ,  CHUAQUI, Claudio ,  SINGH, Juswinder ,  BORIACK-SJODIN, Paula ,  CHOI, Michael, S.

Inventor： LEE, Wen-Cherng ,  CARTER, Mary, Beth ,  SUN, Lihong ,  CHUAQUI, Claudio ,  SINGH, Juswinder ,  BORIACK-SJODIN, Paula ,  CHOI, Michael, S.

IPC: A61K

CPC classification number: C07D471/04 ,  C07D471/02 ,  C07D487/04

Abstract: Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I:

Abstract translation: 式I化合物对Alk5和/或Alk4具有意想不到的高亲和力，并且可用作其拮抗剂用于预防和/或治疗许多疾病，包括纤维化疾病。 在一个实施方案中，本发明的特征在于式I的化合物：

公开(公告)号：WO0218540A3

公开(公告)日：2003-12-24

申请号：PCT/US0127361

申请日：2001-08-31

Applicant: BIOGEN INC ,  ZHENG ZHONGLI ,  CARTER MARY-BETH ,  LIAO YUSHENG ,  SUN LIHONG ,  KIRKOVSKY LEONID ,  MROSE SUSAN ,  HSU YEN-MING ,  DAVID THOMAS ,  SHIPPS GERALD W JR ,  JINDAL SATISH ,  LENZ GEORGE R ,  NASH HUW M

Inventor： ZHENG ZHONGLI ,  CARTER MARY-BETH ,  LIAO YUSHENG ,  SUN LIHONG ,  KIRKOVSKY LEONID ,  MROSE SUSAN ,  HSU YEN-MING ,  THOMAS DAVID ,  SHIPPS GERALD W JR ,  JINDAL SATISH ,  LENZ GEORGE R ,  NASH HUW M

IPC: F25B9/00 ,  A61K31/444 ,  A61P1/04 ,  A61P1/16 ,  A61P9/02 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/06 ,  A61P19/02 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  C07C311/47 ,  C07D401/14 ,  F25B9/14

CPC classification number: A61K31/444 ,  C07C311/47 ,  C07D401/14 ,  F25B9/10 ,  F25B9/145 ,  F25B2309/1408 ,  F25B2309/1411 ,  F25B2309/1418 ,  F25B2309/1424 ,  F25B2309/14241

Abstract: The present invention relates to novel CD40:CD154 binding interruptor compounds of the formula (I), and use of these compounds and pharmaceutical compositions comprising them, to treat conditions associated with inappropriate CD154 activation in a subject. Specifically, this invention provides compounds which are identified by screening a library of small molecules for those that are capable of specifically binding CD154 and interrupting CD40:CD154 interaction.

Abstract translation: 本发明涉及式（I）的新型CD40：CD154结合阻断剂化合物，以及包含它们的这些化合物和药物组合物的用途，以治疗与受试者不适当的CD154活化相关的病症。 具体地，本发明提供了通过筛选能够特异性结合CD154并中断CD40：CD154相互作用的那些的小分子文库来鉴定的化合物。

公开(公告)号：WO2007059359A3

公开(公告)日：2007-05-24

申请号：PCT/US2006/045095

申请日：2006-11-21

Applicant: BIOGEN IDEC MA INC. ,  LEE, Wen-Cherng ,  CARTER, Mary, Beth ,  CHUAQUI, Claudio ,  GUCKIAN, Kevin ,  LIN, Edward, Yin-shiang ,  CHOI, Michael, J. ,  DENG, Zhan ,  BORIACK-SJODIN, Paula, Ann ,  SUN, Lihong

Inventor： LEE, Wen-Cherng ,  CARTER, Mary, Beth ,  CHUAQUI, Claudio ,  GUCKIAN, Kevin ,  LIN, Edward, Yin-shiang ,  CHOI, Michael, J. ,  DENG, Zhan ,  BORIACK-SJODIN, Paula, Ann ,  SUN, Lihong

IPC: C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D419/14 ,  A61K31/4184 ,  A61P35/00

Abstract: The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.

公开(公告)号：WO2007059359A2

公开(公告)日：2007-05-24

申请号：PCT/US2006045095

申请日：2006-11-21

Applicant: BIOGEN IDEC INC ,  LEE WEN-CHERNG ,  CARTER MARY BETH ,  CHUAQUI CLAUDIO ,  GUCKIAN KEVIN ,  LIN EDWARD YIN-SHIANG ,  CHOI MICHAEL J ,  DENG ZHAN ,  BORIACK-SJODIN PAULA ANN ,  SUN LIHONG

Inventor： LEE WEN-CHERNG ,  CARTER MARY BETH ,  CHUAQUI CLAUDIO ,  GUCKIAN KEVIN ,  LIN EDWARD YIN-SHIANG ,  CHOI MICHAEL J ,  DENG ZHAN ,  BORIACK-SJODIN PAULA ANN ,  SUN LIHONG

CPC classification number: C07D403/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D419/14

Abstract: The invention is related to compounds of formula (I) as antagonists of the TGFß family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFß family signaling activity is desirable.

Abstract translation: 本发明涉及作为TGFβ家族I型受体拮抗剂的式（I）化合物，Alk5和/或Alk4，组合物和使用方法。 式（I）化合物可用于预防和/或治疗诸如纤维化（例如肾纤维化，肺纤维化和肝纤维化），进行性癌症或其他TGFβ家族信号活性降低的疾病 是可取的。

公开(公告)号：WO2004021989A3

公开(公告)日：2004-09-23

申请号：PCT/US0327721

申请日：2003-09-05

Applicant: BIOGEN IDEC INC ,  LEE WEN-CHERNG ,  CARTER MARY BETH ,  SUN LIHONG ,  CHUAQUI CLAUDIO ,  SINGH JUSWINDER ,  BORIACK-SJODIN PAULA ,  CHOI MICHAEL J

Inventor： LEE WEN-CHERNG ,  CARTER MARY BETH ,  SUN LIHONG ,  CHUAQUI CLAUDIO ,  SINGH JUSWINDER ,  BORIACK-SJODIN PAULA ,  CHOI MICHAEL J

IPC: A01N20060101 ,  A01N43/00 ,  A61K20060101 ,  A61K31/535 ,  C07D20060101 ,  C07D237/00 ,  C07D237/26 ,  C07D239/00 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D471/02 ,  C07D487/04

Abstract: Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of formula I:

Abstract translation: 式I化合物对Alk 5和/或Alk 4具有出人意料的高亲和力，并且可用作其拮抗剂，用于预防和/或治疗许多疾病，包括纤维化疾病。 在一个实施方案中，本发明的特征在于式I的化合物：

公开(公告)号：WO1997003094A1

公开(公告)日：1997-01-30

申请号：PCT/US1996011570

申请日：1996-07-11

Applicant: BIOGEN, INC. ,  LIN, Ko-Chung ,  ADAMS, Steven, P. ,  CASTRO, Alfredo, C. ,  ZIMMERMAN, Craig, N. ,  CUERVO, Julio, Hernan ,  LEE, Wen-Cherng ,  HAMMOND, Charles, E. ,  CARTER, Mary, Beth ,  ALMQUIST, Ronald, G. ,  ENSINGER, Carol, Lee

Inventor： BIOGEN, INC.

IPC: C07K14/78

CPC classification number: C07K5/0821 ,  A61K38/00 ,  C07K5/0202 ,  C07K5/021 ,  C07K5/06034 ,  C07K5/06113 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0815 ,  C07K5/0819 ,  C07K5/101 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1024 ,  C07K14/78 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/863 ,  Y10S514/866 ,  Y10S514/885 ,  Y10S514/903 ,  Y10S530/868

Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical composition of this inveniton can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

Abstract translation: 本发明涉及可用于抑制和预防细胞粘附和细胞粘附介导的病理学的新型化合物。 本发明还涉及包含这些化合物的药物制剂及其用于抑制和预防细胞粘附和细胞粘附介导的病理学的方法。 本发明化合物和药物组合物可用作治疗或预防剂。 它们特别适用于治疗许多炎性和自身免疫性疾病。